Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer
Kristen K. Ciombor(Vanderbilt University Medical Center), H. Charles Manning(The University of Texas MD Anderson Cancer Center), Cathy Eng(Vanderbilt University), Todd E. Peterson(Vanderbilt University), Dana B. Cardin(Vanderbilt University Medical Center), Gregory D. Ayers(Vanderbilt University), Saikat Chowdhury(The University of Texas MD Anderson Cancer Center), Kangyu Lin(The University of Texas MD Anderson Cancer Center), Jordan Berlin(Dana-Farber Cancer Institute), Quanhu Sheng(Cancer Research And Biostatistics), Alexey V. Sorokin(The University of Texas MD Anderson Cancer Center), Yu Shyr(Vanderbilt University), Preeti Kanikarla Marie(The University of Texas MD Anderson Cancer Center), Jennifer G. Whisenant(Vanderbilt-Ingram Cancer Center), Seong-Woo Bae(The University of Texas MD Anderson Cancer Center), Laura W. Goff(Vanderbilt University Medical Center), Gary T. Smith(VA Tennessee Valley Healthcare System), Scott Kopetz(The University of Texas MD Anderson Cancer Center), Allison S. Cohen(Washington University in St. Louis), John Paul Shen(The University of Texas MD Anderson Cancer Center)
Cited by 16
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k